Lexaria Bioscience Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LEXX research report →
Companywww.lexariabioscience.com
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery.
- CEO
- Richard C. Christopher
- IPO
- 2021
- Employees
- 7
- HQ
- Kelowna, BC, CA
Price Chart
Valuation
- Market Cap
- $12.26M
- P/E
- -1.54
- P/S
- 33.32
- P/B
- 2.22
- EV/EBITDA
- -0.76
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 76.20%
- Op Margin
- -2513.78%
- Net Margin
- -2589.65%
- ROE
- -190.06%
- ROIC
- -146.73%
Growth & Income
- Revenue
- $705.92K · 52.05%
- Net Income
- $-11,901,841 · -105.37%
- EPS
- $-0.66 · -40.43%
- Op Income
- $-11,633,373
- FCF YoY
- -109.42%
Performance & Tape
- 52W High
- $1.55
- 52W Low
- $0.46
- 50D MA
- $0.79
- 200D MA
- $0.87
- Beta
- 0.36
- Avg Volume
- 181.35K
Get TickerSpark's AI analysis on LEXX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 17, 26 | BUNKA CHRISTOPHER | other | 100,000 |
| Jul 30, 25 | BUNKA CHRISTOPHER | buy | 11,900 |
| Jul 29, 25 | BUNKA CHRISTOPHER | buy | 15,600 |
| Jul 29, 25 | McKechnie William Edward | buy | 5,000 |
| Jul 29, 25 | DOCHERTY JOHN MARTIN | buy | 5,376 |
| Jul 29, 25 | Carle Vanessa | buy | 750 |
| Jul 29, 25 | CHRISTOPHER RICHARD | buy | 15,000 |
| May 15, 25 | CHRISTOPHER RICHARD | other | 150,000 |
| May 15, 25 | BUNKA CHRISTOPHER | other | 11,000 |
| May 15, 25 | Carle Vanessa | other | 15,000 |
Our LEXX Coverage
We haven't published any research on LEXX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LEXX Report →